- Conditions
- RSV Infection
- Interventions
- RSVpreF, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 265
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALN-RSV01, normal saline
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Denver, Colorado + 7 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Newton, Kansas • Syracuse, New York • Ellensburg, Washington
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- IQuum, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more
- Conditions
- Covid19
- Interventions
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
- Biological
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Raleigh, North Carolina
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Interventions
- mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
- Conditions
- Respiratory Tract Infection
- Interventions
- Formulation A, Formulation B, Formulation C, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
- Conditions
- RSV Infection
- Interventions
- GS-5806
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Moderna RSV vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA BN RSV, Placebo
- Biological · Other
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MEDI8897, Placebo
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 365 Days
- Enrollment
- 1,453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Anaheim, California • Downey, California + 53 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MEDI ΔM2-2 vaccine, Placebo vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 49 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- MEDI-559, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 23 Months
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 75
- States / cities
- Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
- Conditions
- SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
- Interventions
- Not listed
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Metairie, Louisiana • New Orleans, Louisiana
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- Respiratory Syncytial Virus Infections, Virus Diseases
- Interventions
- JNJ-53718678, Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 1 Month to 24 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 1030s vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV ΔNS2/Δ1313/I1314L, RSV 276, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Infections, Acute, Respiratory Syncytial Virus
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 1,401 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Influenza, Human, Respiratory Syncytial Virus Infections
- Interventions
- Swab
- Diagnostic Test
- Lead sponsor
- LumiraDx UK Limited
- Industry
- Eligibility
- Not listed
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Encinitas, California • Madera, California + 17 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Detroit, Michigan • Minneapolis, Minnesota + 6 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALS-008176, Placebo
- Drug
- Lead sponsor
- Alios Biopharma Inc.
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more